Проект Рак молочної залози
жүктеу/скачать 1.3 Mb.
|
- Бұл бет үшін навигация:
- ВЕДЕННЯ РАКУ МОЛОЧНОЇ ЗАЛОЗИ У ЖІНОК
- ХІРУРГІЯ ОПЕРАЦІЯ ЗІ ЗБЕРЕЖЕННЯМ МОЛОЧНОЇ ЗАЛОЗИ ПРОТИ мастектоміЇ
- Біологічна терапія
- Дослідження ► Бісфосфонати
- Лікування симптомів менопаузи
- СИСТЕМНА ТЕРАПІЯ ► Ад’ювантна хіміотерапія ►Визначення психологічних порушень
- Психологічна підтримка жінок з раком молочної залози і їх сімей
- ПРОМЕНЕВА ТЕРАПІЯ ► Ад’ювантна променева терапія
- Психологічна допомога
- СПИСОК
ДОДАТОК 3 Визначення стадії TNM Т - первинна пухлина TX — первинну пухлину не можливо оцінити Т0 — немає свідчень про первинну пухлину Tis — карцинома in situ: внутрішньопротокова карцинома, лобулярна карцинома in situ, або хвороба Педжета соска без пухлини 1 T1 — пухлина розміром 2см або менше у найбільшому вимірі2
T1b — більша 0,5 см, але не більша 1 см у найбільшому вимірі T1c — більша 1 см, але не більша 2 см у найбільшому вимірі T2 — пухлина більша 2 см, але не більша 5 см у найбільшому вимірі T3 — пухлина більша 5 см у найбільшому вимірі T4 —пухлина будь-якого розміру з прямим поширенням у грудну стінку3 або шкіру T4a — поширення в грудну стінку T4b — набряки (у тому числі апельсинова кірка), або виразки шкіри молочної залози або супутникові шкірні вузлики обмежені у тій же груді T4с — як 4а, так і 4б вище T4d запальна карцинома4 N - ураження регіонарних лімфатичних вузлів NX — регіонарні лімфатичні вузли не можуть бути оцінені (наприклад, раніше видалені) N0 — немає метастазів у регіонарних лімфатичних вузлах N1 — метастази в рухомі іпсилатеральні пахвові лімфатичні вузли (и)
N3 метастази в іпсилатеральні внутрішні лімфатичні вузли молочних залоз М – дистальні метастази NX — дистальні метастази не можуть бути оцінені М0 — немає дистальних метастазів M1 — дистальний метастаз Примітки: 1.хвороба Педжета, пов'язана з пухлиною, класифікується в залежності від розмірів пухлини 2. Мікроінвазія — це поширення ракових клітин поза мембрану в прилеглі тканини з фокусом не більше 0.1 см у найбільшому вимірі. Якщо є декілька осередків мікроінвазії, використовується розмір найбільшої для класифікації мікроінвазії. (Не використовуйте суму всіх мікроінвазій) Наявність множинних осередків мікроінвазії повинна бути зазначена, як це є з карциномою з більшою інвазією. 3. Стінка грудної клітки включає ребра, міжреберні м'язи і зубчасті передні м'язи, але не м'язи грудної клітки 4. Запальна карцинома молочної залози характеризується дифузним затвердінням шкіри з еризопелоїдним краєм, як правило, без основної маси. Якщо біопсія шкіри негативна і немає локалізованого вимірюваного первинного раку, категорія Т — це рTX при патологічній стадії клінічного запального раку (T4d). Ямочки на шкірі, втягування сосків або інші зміни шкіри, за винятком тих, що є при T4b і T4d можуть бути при T1, T2 або T3, не впливаючи на класифікацію. Source, International Union Against Cancer (UlCC). TNM Classification of malignant tumours- Edited by LH Sobin and Cb. Wittekind. 5th ed. New York Witey-Liss; 1997. ВЕДЕННЯ РАКУ МОЛОЧНОЇ ЗАЛОЗИ У ЖІНОК
СПИСОК ЛіТЕРАТУРи, представлений в прототипі клінічної настанови SIGN Guideline 84: Breast Cancer in Women (2005). 1 Information and Statistics Division Scotland- Information and Statistics. Cancer Breast. Overview, [cited 3 October 2005] Available from url: http://www.isdscotland.org/isd cancer_definition. J5p!pContentlD= 1420&p_applic=CCC&p_service=Content show* 2 Scottish Intercollegiate Guidelines Network (SIGN). Breast cancer in women. Edinburgh: SIGN; 1998. (SIGN publication no. 29). 3 Scottish Intercollegiate Guidelines Network (SIGN). A guideline developer's handbook- Edinburgh:SIGN;2004 (SIGN publication no. 50). [cited 1 September 2005]. Available from url: http://www.5ign. ac.uk 4 NHS Breast Screening Programme. Breast screening: a pocket guide. Sheffield: The Programme; 2002. [cited 13 Jun 2005].Available from url: http:/Avww.cancerscreening-nhs.uk/breast5creen/publicatkms/ia-01 html 5 Chiu LF. Straight talking: communicating breast screening information in primary care. Leeds: Nuffield Institute for Health, 2002.[cited 13 Jun 2005] Available from url: http://www.cancerscreenmg.nhs.uk/ breastscreen/publications/ pc-06.html 6 Mclntosh A, Shaw C, Evans G, Turnbull N, Bahar N, Barclay M, et al Clinical guidelines and evidence review for the classification and care of women at risk of familial breast cancer. London: National Collaborating Centre for Primary Care/University of Sheffield; 2004. [cited 14 Jun 2005] Available from url: http://www.nice.org.uk/page. aspx?o-2Q3183 7 Scottish Intercollegiate Guidelines Network (SIGN). Long term tallow up of survivors of childhood cancer. Edinburgh: SIGN, 2004. (SIGN publication no. 76). 8 Thomas DB, Gao DL, Ray RM, Wang WW, Allison C), Chen FL. Randomized trial of breast self-examination in Shanghai: final results. I Natl Cancer Inst 2002,94(19):1445-S7. 9 Kosters JP. G0tzsche PC Regular self-examination or clinical examination for early detection of breast cancer (Cochrane Review). In: The Cochrane Library, Issue 3, 2004 Chichester, UK: John Wiley & Sons, Ltd. 10 Austoker j. Screening and self examination for breast cancer. In: Cancer prevention in primary care. London: BMJ Publishing Group, 1995. p. 75-94. 11 NHS Breast Screening Programme. Quality assurance guidelines for radiologists. Sheffield: The Programme; 1997. (NHSBSP publication no. 15). 12 Stokell Pj, Robb )D. SPIDER-1 Software for evaluating the detriment associated with radiation exposure. Chiiton: National Radiological Protection Board; 1993. 13 Royal College of Radiologists. NHS Breast Screening Programme. London: The College; 1997 14 Law I Risk and benefit associated with radiation dose in breast screening programmes-art update Br) Radiol 1995;68:870-6. 15 Young KC, Ramsdale ML, Rust A. Mammographic dose and image quality in the UK Breast Screening Programme. Sheffield: NHS Breast Screening Programme; 1995. (NHSBSP publication no. 35). 16 Young KC, Ramsdale ML, Rust A. National survey of mammographic image quality and dose in the UK Breast Screening Programme. Sheffield: NHS Breast Screening Programme; 1998 (NHSBSP publication no. 37). 17 Burch A, Goodman DA. A pilot survey of radiation doses received in the United Kingdom Breast Screening Programme. Br J Radiol 1998,71:517-27 18 Austoker J, Mansel R, Baum M, Samsbury R, Hobbs R. Guidelines for referral of patients with breast problems 2nd revised ed. Sheffield: NHS Cancer Screening Programmes, 2003. [cited 21 June 2005]. Available from url: http://www.cancerscreerting.nhs.uk/breastscreen/publications/ pc-rgfw-01.html 19 Dixon JM, Mansel RE. Symptoms, assessment and guidelines for referral In: Dixon 1M, editor. ABC of breast diseases. London: BMj Publishing Group, 1995. p. 1-5. 20 Scottish CancerGroup. Scottish referral guidelines for suspected cancer. February 2007, [cited Mar 13 2007], available from url: http://www. sehd.5cot.rths.uk/mels/HDL2007_09.pdf 21 Richards, M. A., Westcombe, A. M., Love, S. B . Littlejohns, P and Ramirez, A. J. Influence of delay on survival in patients with breast cancer: A systematic review. Lancet 1999:353;1119-1126. 22 Morris KT, Pommier RF, Morris A, Schmidt WA, Beagle G, Alexander PW, et al. Usefulness of the triple test score for palpable breast masses. Arch Surg. 2001; 136:1008-13 23 Eltahir A, Jibril JA, Squair J, Heys SD, Ah-See AK, Needham G, et al. The accuracy of "one-stop" diagnosis for 1,110 patients presenting to a symptomatic clinic. J R Coll Surg Edinb 1999,44:226-30. 24 Scottish Intercollegiate Guidelines Network (SIGN). The Immediate Discharge Document Edmburgh:SIGN; 2003. (SIGN publication no. 65). [cited 2 June 2004]. Available frprti url: http://www.sign.ac.uk/ 25 HarcourtD, Ambler N. RumseyN,CawthornS].Evaluattonofaone-stop breast lump clinic, a randomized controlled trial. Breast 1998:7(6);314-9 26 Dey P, Bundred N, Gibbs A, Hopwood P, Baildam A, Boggis C., et al. Costs and benefits of a one stop clinic compared with a dedicated breast clinic: randomised controlled trial. BMj 2002:324(73361,507 27 Harms SE, FlamigDP. MR imaging of the breast. J Magn Reson Imaging 1993,3:277-83. 28 Stelling CB. MR imaging of the breast for cancer evaluation. Current status and future direction. Radiolog Cltn North Am 1995;33:1187-204. 29 Weinreb JC, Newstead G. MR imaging of the breast. Radiology 1995;196:593-610. 30 Khatri VP, Stuppino JJ, Espinosa MH, Pollack MS. Improved accuracy in differentiating malignant from benign mammographic abnormalities Cancer 2001,92: 471-8. 31 Kristoffersen Wiberg M, Aspelin P, Perbeck I. Bone B. Value of MR Imaging in Clinical Evaluation of Breast Lesions. Acta Radiologice 2Q02;43:275-81. 32 Drew PJ, Turnbull LW, Chatterjee S, Read j, Carleton PJ, Fox JN, et al. Prospective comparison of standard triple assessment and dynamic magnetic resonance imaging of the breast for the evaluation of symptomatic breast lesions. Ann Sufg 1999;230:68Q-5. 33 International Consensus Conference - Image-detected breast cancer: state of the art diagnosis and treatment. Breast (. 2002;8(2):70-6 34 Azzarelli A, Guzzon A, Piiotti S, Quagliuolo V, Bono A, Di Pietro S Accuracy of breast: cancer diagnosis by physical, radiologic and cytologic combined examinations. Tumori 1983, 69: 137-41. 35 Dixon JM, Anderson TJ, Lamb J, Nixon Sj, Forrest AP. Fine needle aspiration cytology in relationship to clinical examination and mammography in the diagnosis of a solid breast mass. Br J Surg 1984; 71:593-6 36 Di Pietra 5, Fariselli G, Bandieramonte G, Lepera P, Cooprnans de Yoldi G, Viganotti G, et al. Diagnostic efficacy of the cltmcal-radiological-cvtological triad in solid breast lumps: results of a second prospective study on 631 patients. Eur J Surg Oncol 1987; 13: 335-40. 37 Hermansen C, Skovgaard Poulsen H, Jensen j, Langfeldt B, Steenskov V, Frederiksen P, et al. Diagnostic reliability of combined physical examination, mammography and fine-needle puncture ("triple-test") in breast tumours. A prospective study. Cancer 1987; 60: 1866-71. 38 Butler JA, Vargas HI, Worthen N, Wilson SE. Accuracy of combined clinical-mam mographic-cytologic diagnosis of dominant breast masses A prospective study Arch Surg 1990; 125: 893-6 39 Martelli G, Piiotti S, Coopmans de Yoldi G, Viganotti G, Fariselli G, Lepera P, et al. Diagnostic efficacy of physical examination, mammography, fine needle aspiration cytology (triple-test! in solid breast lumps: an analysis of 1708 consecutive cases. Tumori 1990; 76: 476-9 40 Bassett LW, Ysrael M, Gold RH, Ysrael C. Usefulness of mammography and sonography in women less than 35 years of age Radiology 1991, 180:831-5. 41 Breast Surgeons Group of the British Association of Surgical Oncology. Guidelines for surgeons in the management of symptomatic breast disease in the United Kingdom. Eur J Surg Oncol 1995, 21 (Suppl A): 1-13. 42 Cancer Care Ontario. Breast Cancer Disease Site Group.Surgical management of early stage invasive breast cancer. 2003.Toronto;Cancer Care Ontario:2003.(Practice Guideline Report #1-1 Version 2) [cited 12 July 2005]. Available from URL:http://www.cancercare.on.ca/pdf/ pebcl-lfpdf 43 Veronesi U, Cascmelli N, Mariani L, Greco M,Saccozzi R, Lumi A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002,347(16):1227-32. 44 Fisher B, Anderson S, Bryant j, Margolese RG. Deubch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer N Engl J Med. 2002,347(16):1233-41. 45 Curran D, van Dongen JP, Aaronson NK, KiebertG, Fentiman IS, Mignolet F, et al. Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: results of EORTC Trial 10801 The European Organization for Research and Treatment of Cancer (EORTQ, Breast Cancer Co-operative Group (BCCC). Eur I Cancer. 1998.34{3):307-14. 46 Veronesi U, Marubini E, Mariani L, Galimberti V, Luini A, Veronesi P, et al Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol 2001;12(7):997-1003. 47 Holli K. Saaristo R, Isola J, joensuu H, Hakama M. Lumpectomy with or without postoperative radiotherapy for breast cancer with favourable prognostic features: results of a randomized study Br ] Cancer. 2001;84(2):l64-9 48 Fisher ER, Anderson S, Tan-Chiu E, Fisher B, Eaton L, Wotmark N. Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06. Cancer 2001 ;91 (8 Supplj:! 679-87. 49 Codner A, Bostwick J A review of breast reconstruction after mastectomy Breast 1995;4:4-10. 50 Thomas PR, Ford HT, Cazet JC. Use of silicone implants after wide local excision of the breast. Br I Surg 1993,80:868-70 51 Abbes M, Huss M. Breast and chest wall reconstruction by latissimus dorsi myocutaneious flap (238 cases). Breast 1995;4:33-9. 52 Lemperle G, Nievergelt J, Park F. Nipple-areoia reconstruction. In: Plasticand reconstructive breast surgery-an atlas. Berlin:Springer;1991 p.141-55. 53 Watson JD, Samsbury JR, Dixon JM. ABC of breast diseases. Breast reconstruction after surgery BMJ 1995,310:117-21. 54 Malata CM, Sharpe DT On the safety of breast implants Breast 1992;1:62-75 55 Veronesi U, Luini A. Galimberti V, Marchim S, Sacchini V, Rilke F. Extent of metastatic axillary involvement in 1446 cases of breast cancer EurJ SurgOncol 1990;l6:127-33. 56 Veronesi U, Galimberti V, Zurrida S, Mersort M, Greco M, Lumi A. Prognostic significance of number and level of axillary node metastases in breast cancer. The Breast 1993;2:224-fl. 57 Chetty U, Jack W, Prescott RJ, Tyler C, Rodger A. Management of the axilla in operable breast cancer treated by breast conservation: a randomized clinical trial. Edinburgh Breast Unit. Br j Surg. 200D;87(2): 163-9 58 Fisher B, Redmond C, Fisher ER, Bauer M, Wblmark N, Wickerham DL, et at. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl 1 Med. 1985;312(11):674-81. 59 Australia. National Health and Medical Research Council. Clinical practice guidelines for the management of early breast cancer. 2™* ed. Canberra:The Council:2001. (Guideline CP74). [cited 12 fuly 2005]. Available from URL: http://www.nhmrc.gov.au/publications/synopses/ cp74syn.htm 60 NHS Breast Screening Programme. Pathology reporting in breast cancer screening. 2nd ed. Sheffield: The Programme; 1997 Feb. NHSBSP Publication No 3. 61 Fisher ER, Leeming R, Anderson S, Redmond C, Fisher B. Conservative management of intraductal carcinoma (DCIS) of the breast. Collaborating NSABP investigators. J SurgOncol. 1991;47(3):139-47. 62 Yin XP, Li XQ, Neuhauser D, Evans JT. Assessment of surgical operations for ductal carcinoma in situ of the breast. Int { Technol Assess Health Care. 1997;13(3):420-9. 63 Fisher B, Digram), Wolmark N, Mamounas E, Costantino J, Poller W,et al. Lumpectomy and radiation therapy far the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998,16(2):441-52. 64 Julien JP, Bijker N, Fentiman IS, PeterseJL, Delledonne V, Rouanet P, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group Lancet. 2000;355(9203):528-33. 65 Houghton J, George WD, Cuzicfc J, Duggan C, Fentiman IS, Spittle M, UK Coordinating Committee on Cancer Research; Ductal Carcinoma in situ Working Party; DCIS trialists in the UK, Australia, and New Zealand-Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362(9378):95-102. 66 Whelan TJ, Lada BM, Laukkanen E, Perera FE, Shelley WE, Levine MN, and the Provincial Breast Disease Site Group. Breast irradiation in women with early stage invasive breast cancer following breast conservation surgery. Cancer Prevention & Control 1997;3:228-240. 67 Silverstein MJ, Lagios MD, Groshen S, Waisman JR, Lewinsky BS, Marti no S, etal. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl f Med. 1999;340(19): 1455-61 68 Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial Lancet 1999;353:1993-2000. 69 Cancer Care Ontario. Breast Cancer Disease Site Group. Management of ductal carcinoma in situ of the breast: Toronto;Cancer Care Ontario:2Gt)3 (Practice Guideline Report #1-10). [cited 12 July 2005]. Available from URL: http://www.cancercare.on.ca/pdf/fulll_1Q.pdf 70 Chua B, Olivotto IA, Weir L, Kwan W, Truong P, Ragaz J Increased use of adjuvant regional radiotherapy for node-positive breast cancer in British Columbia. Breast}. 20Q4;100):38-44. 71 Whelan TJ, Julian J, Wright J, Jadarf AR, Levine ML. Does locoregional radiation therapy improve survival in breast cancer? A meta-anaiysis. J Clin Oncol 20DQ,lB(6):1220-9 » 72 Early Breast Cancer Trialists' Collaborative Group. Radiotherapy for early breast cancer (Cochrane Review). In: TheCochrane Library, Issue 2, 2002 Oxford: Update Software. 73 Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy far early breast cancer an overview of the randomised trials. Lancet. 2000; 355(9217): 1757-70. 74 Mafmstrom P, Holmberg L, Anderson H, Mattsson J, Jonsson PE, Tennvall-Nittby L, et al. Breast conservation surgery, with and without radiotherapy, in women with lymph node-negative breast cancer a randomised clinical trial in a population with access to public mammography screening. Eur j Cancer 2003;39:1690-7. 75 Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer: an overview of the randomised trials N Engl J Med 1995,333:1444-1455. 76 Lee HD, Yoon DS, KooJY, Suh CO, Jung WH, Oh KK. Breast conserving therapy in stage I & II breast cancer in Korea. Breast Cancer Res Treat 1997;44:193-9. 77 Recht A, Edge SB, Solin LJ, Robinson DS, Estabrook A, Fine RE, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19(5):1539-69 78 Kuske RR, Hayden D, Bischoff R, etal: The impact of extracapsuiar axillary nodal extension (ECE) with and without irradiation on patterns of fai lure and survival from breast cancer. Int 1 Radiat Oncol Biol Phys 36:277, 1996(suppl l.abstr). 79 Ewers SB, Attewell R, Baldetorp B, Borg A, Ferno M, Langstrom E, et: al. Flow cytometry DNA analysis and prediction of loco-regional recurrences after mastectomy in breast cancer. Acta Oncol. 1992;31(7):733-40. 80 Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE. et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997;337(14):956-62. 81 McArdfe CS, Crawford D, Dykes EH, Caiman KC, Hole D, Russell AR, et al. Adjuvant radiotherapy and chemotherapy in breast cancer. Br J Surg. 1986,73(4):264-6. 82 Lacour J, Le M. Caceres E, Koszarovvski T, Veronesi U, Hill C- Radical mastectomy versus radical mastectomy plus internal mammary dissection- Ten year results of an international cooperative trial in breast cancer. Cancer. 1983;51(10):1941-3. 83 Veronesi U, Marubini E, Mariani L, Valagussa P, Zucati R. The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial. Eur J Cancer. 1999;35(9):1320-5. 84 Yamashita T, Hurukawa M, Sekiguchi K, et al: Efficacy of loco-regional lymph nodes irradiation after mastectomy for breast cancer with biopsy proven lymph nodes metastases: A randomized study. Int ] Radiat Oncol Biol Phys 36:277, 1996 (suppl 1, abstr) 85 Freedman CM, Fowble BL, Nicolaou N, Sigurdson ER, Torosian MH, Boraas MC, et al. Should internal mammary lymph nodes in breast cancer be a target for the radiation oncologist? Int J Radiat Oncol Biol Phys. 2000;46(4):805-14. 86 Bellon JR, Come SE, Gelman RS, Henderson 1C, Shulman LN, Silver BJ, et at. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial, j Clin Oncol. 2005;23(9): 1934-40. 87 Whelan TJ, Lada BM, Laukkanen E, Perera FE, Shelley WE, Levine MN Breast irradiation in women with early stage invasive breast cancer fallowing breast conservation surgery. Provincial Breast Disease Site Group. Cancer Prev Control. 1997,1 (3):228-40. 88 National Institute for Clinical Excellence. Improving outcomes for breast cancer: research evidence far the manual update.York, NHS Centre for Reviews and Sissemination:2002. 89 NHS Quality Improvement Scotland. Breast cancer services: national overview. Edinburgh:NHSQIS:2003. [cited 12July 2005] Available from URL: http://www.nhshealthquality org/nhsqis/files/breast_overview. pdf 90 Yamada Y, Ackerman I, Franssen E, MacKenzie RG, Thomas G. Does the dose fractionation schedule influence local control of adjuvant radiotherapy for early stage breast cancer? Int J Radiat Oncol Biol Phys 1999;44(1):99-104 91 Cancer Care Ontario. Breast Cancer Disease Site Group Use of Bisphosphonates in women with breast cancer. Toronto;Cancer Care Ontano:2004. (Practice Guideline Report #1-11 Version 2.2002) [cited 2 June 2004]. Available from URL: http//www.cancercare.on.ca/pdf/ pebc1-1lf.pdf 92 Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group-Lancet. 1998;352(9132):930-42. 93 Bonadonna G., Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results JAMA 1995;273:542-47 94 Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, etal. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. ] Ciin Oncoi 2003,21(8):1431-39. 95 Fomier MN, Seidman AD, Theodoulou M, Moynahan ME, Currie V, Moasser M, et al Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase \\ randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. Clin Cancer Res 2001,7(12):3934-41. 96 Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan |, Savin M, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002,20(3):727-31. 97 Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Nat! Cancer Inst 2Q01;93(12):913-20. 98 Amadori D, Nanni O, Marangolo M, Pacini P, Ravaioli A, Rossi A, et al. Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study-. J Clin Oncol 2000;18(1 7):3125-34. 99 VVhelan T, Sawka C, Levine M, Gafni A, Reyno L, Willan A, et al Helping patients make informed choice. J Natl Cancer Inst 2003; 95(8): 581-7. 100 Berglund C, Nystedt M, Bolund C, Sjoden PO, Rutquist LE. Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized study, j Clin Oncol 2001,19(11): 2788-96. 101 Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Romeo D, Sismondi P, et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 2000;18(14): 2718-27 102 Jonat W, Kaufmann M, Sauerbrei W, Blarney R, Cuzick), Namer M, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002,20(24): 4628-35. 103 Schmid P, Untch M, Wallwiener D, Kosse V, Bondar G, Vassiljev L, et al Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Anticancer Res 2002;22(4): 2325-32. 104 jakesz R, Hausmanmger H, Kubista E, Gnant M, Menzel C, Bauemhofer T, et al Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer—Austrian Breast and Coiorectal Cancer Study Group Trial 5. j Clin Oncol 2002;20(24): 4621-7 105 Vorgias G, Koukouras D, Tzoracoeleftherakis E, Paleogianni V, Androulakis J. Adjuvant tamoxifen versus tamoxifen plus CMF in the treatment of early breast cancer in Greece. Fifteen-year results of a randomised prospective trial and the potential risks of the antioestrogen. Anticancer Res 2000;20(5C): 3849-54 106 Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins ), Thurl imann B, et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000; 355:1869-74. 107 Powles TJ, Hickish TF, Makris A, Ashley SE, O'Brien ME, Tidy VA, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.) Clin Oncol. 1995;! 3(3):547-52 108 van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19(22):4224-37. 109 Deo SV, Bhutani M, Shukla NK, Rama V, Rath GK, Purkayasth j. Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b NO-2 MO). J Surg Oncol. 2003;84(4): 192-7. 110 Heys SD, Huteheon AW, Sarkar TK, Ogstan KM, Miller ID, Payne S, et al Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002;(3 Suppl 2):S69-S74. 111 Cocconi G, Di Bbsio B, Boni C, Bisagm G, Ceci G, Rondini E, et al Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.. Cancer 2002,95(2): 228-35. 112 Levine MN, Bramwell VH, Pritchard Kl, Morris BD, Shepherd LE, Abu-Zahra H, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.) Clin Oncol 1998;1&(Bj:2651-58 113 Henderson 1C, Berry DA, Demetri CD, Cirrincione CT, Goldstein LJ. Martino S, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21(6):976-83. 114 Cancer Care Ontaria. Breast Cancer Disease Site Group and Systemic Treatment Disease Site Group. Epirubicin, as a single agent or in combination, for metastatic breast cancer. Toronto;Cancer Care Ontario:2002. (Practice Guideline report #1-6.) [cited 12 |uly 20D5J Available from URL: http://www.cancercare.on.ca/pdf/pebc1-6f.pdf 115 British Medical Association Royal Pharmaceutical Society of Great Britain. British National Formulary No. 48. London;BMA:2004. [cited 15 July 2005] Available from URL: http:/Avww.bnf.afg 116 Scottish Medicines Consortium. Pegylated liposomal doxorubicin (Caelyx) Schering-Plough Ltd Indication: metastatic breast cancer. Glasgow;SMC:2D04. [cited on 12July 2005] Available from URL: http://www.scottishmedicines.org.uk/updocs/Pegytated%20Liposorna ft20Doxorubicm%20HCI.pdf 117 Fossati R, Confalonieri C, Torn V, Ghislandi E, Penna A, Pistotti V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.} Clin Oncol. 1998; 16(10):3439-60. 118 Lister-Sharp D, McDonagh MS, Khan KS, Kleijnen J. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in (he treatment of advanced breast and ovarian cancer. Health Technol Assess 2000;4(17):1-113. 119 Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, et al. Prospective randomized trial of docetaxel versus rnitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracyclme-contaming chemotherapy. 304 Study Group. J Clin Oncol. 1999;! 7(5):1413-24. 120 Chan S, Fnedrichs K, Noel D, Pinter T, Van Belle 5, Vorotnof D, et al Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.) Clin Oncol. 1999;17(8):2341-54. 121 Lewis R, Bagnall A M, Forbes C, Shirran E, Duffy S. Kleijnen J, et at. The clinical effectiveness of trastuzumab for breast cancer. Health Techno! Assess 2002;6(13):1-71. 122 Baselga ), Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, etal. Phase 11 study of weekly intravenous recombinant humanized anti-pi 85(HЈR2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996,14(3):737-744. 123 Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, etal. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressmg metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17(9):2639-2648. 124 VogelCL,CobleighMA,TripathyD,GutheilJC,HarrisLN,FehrenbacherL, etal. Efficacy and safety of trastuzumabas a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002:20(3); 719-26. 125 Taylor SG 4th, Gelrnan RS, Falkson G, Cummings FJ. Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med 19S6;104:455-61. 126 Moundsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, etal. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001,19:2596-2606 127 Piccart-Gebhart MJ, Procter M, Lelyand-Jones B, Goldhirsch A, Untch M, Smith I et al Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. N Engl J Med 2005;353:1659-72. 128 Romond EH, Perez EA, Bryant}, Suman V), Geyer CE, Davidson NE, et al. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. N Engl J Med 20O5;353:1673-84. 129 Feldman AM, Lorell BH. Reis 5E. Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity. Circulation 2000;102(3):272-4. 130 Slamon Dj, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl j Med. 2001;344(11):783-92, 131 Pegram MD, Upton A, Hayes DF, Weber 8L, Baselga }M, Tripathy D, et al. Phase !1 study of receptor-enhanced chemosensitivity using recombinant humanized anti-pi 85H(IZ'™" monoclonal antibody plus cispiatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16:2659-71. 132 Fomier MN, Seidman AD, Theodouiou M, Moynahan ME, Currie V, Moasser M, et al. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-Year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma- Clin Cane Res 2001:7(12);3934-41. 133 Cancer Care Ontario Breast Cancer Disease Site Group. Use of Trastuzumab (Herceptin) in metastatic breast cancer. TorantojCancer CareOntario:2002 (Evidence Summary Report #1-15). [cited on 12 July 2005] Available from URL: http://www.cancBrcare.on.ca/pdf/pebc1-1 If. pdf 134 Marty M, Cognetti F, Maraninchi D. Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metasiatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 20Q5;23<191:4265-74. 135 Cancer Care Ontaria. BreastCancer Disease Site Group. Capecitabine in Stage IV breast cancer. Toronta;Cancer Care Ontario:2003. (Practice Guideline Report #1-161 [cited on 2 June 2004]. Available from URL: http://www.cancercare.on.ca/pdf/pebc1-16f.pdf 136 Cancer Care Ontaria. Breast Cancer Disease Site Group. Vinorelbine in stage IV breast cancer, Toronta;Cancer Care Ontario:2003. (Evidence Summary #1^f). [cited on 12 July 2005]. Available from URL: http:// www.cancercare.on.ca/pd 137 Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O'Rourke M et al. Randomized comparison of vinorelbine and melphalan in anthracyctine-refractory advanced breast cancer. J Clin Oncol 1995; 13:2567-74. 138 Venturino A, Comandini D, Simoni C, Merlini L, Naso C, Palurnbo R, et al. Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leueovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin. Breast Cancer Res Treat 2000;60:195-200 139 Norris B, Pritehard Kl, James K, Myles J, Bennett K, Marlin S, etal. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MAS. J Clin Oncol 2000;18:2385-94. 140 Talbot DC, Moiseyenko V, Van Belle S, O'Reilly SM, Alba Cone/o E, Ackland S, et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 20Q2;86:1367-72. 141 Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999,17:485-93. 142 OshaughnessyJA, BlumJ, Moiseyenko V, Jones SE, Miles D, Bell D, etal. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF fcyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12:1247-54. 143 O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V. Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812-23. 144 Pavlakis N, Stockier M. Bisphosphonates for breast cancer (Cochrane Review). In: The Ccchrane Library, Issue 2, 2002. Oxford: Update Software. 2002. 145 Powles T, Paterson S, Kanis f A, McCloskey E, Ashley S, Tidy A, et al. Randomized, placebo-controlled trial of clodranate in patients with primary operable breast cancer. J Clin Oncol 2002;20:3219-24. 146 Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients wrth multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol 1998; 16(3): 1218-25. 147 Cancer Care Ontaria. Breast Cancer Disease Site Group. Adjuvant systemic therapy for node-negative breast cancer. Toronto,Cancer Care Ontaria:2002. (Practice Guideline Report #1-8). [cited 12 July 2005). Available from URL: http-Jwww.ccopebc.ca/guidelines/bre/ cpgl_S.html 148 Rosen LS, Gordon DH, Dugan WJ/, Major P, Eisenberg PD, Provencher L, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least: one osteolytic lesion. Cancer. 2004; 100(11:36-43, 149 Love RR, Due NB, Allred DC, Binh NC, Dinh NV, Kha NN, et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clirt Oncol 2002; 20:2559-66, 150 Tamoxifen for early breast cancer: an overview of the randomised trials. Early BreastCancer Trialists'CollaborativeGroup. Lancet 1998:351(9114): 1451-67. 151 Anonymous, Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London. Lancet. 1993;341 (8856): 1293-8. 152 Kaufmann M, Jonat W, Blarney R, Cuzick J, Namer M. Fogelman I, et al. Survival analyses from the ZEBRA study, goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer. 2003;39(12):1711-7. 153 Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauemhofer T, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer—Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol. 2002;20(24):4621-7. 154 Klijn JG, Blarney RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R; Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer a meta-analysis of four randomized trials. J Clin Oncol. 2001; 19(2):343-53. 155 Gardner FJ, Konje JC, Abrams KR. Brown LJ, Khanna S. AI-Azzawi F,et al. Endometrial protection from tarnoxifen-stimulatedchanges by a levonorgestrel-releasing irrtrauterine system: a randomised controlled trial. Lancet. 2QOD;356(9243):1711-7. 156 Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausa} women with early breast cancer first results of the AT AC randomised trial. Lancet. 2002 ;359(9324):2131-9, 157 Goss PE, Ingle JN, Martino S. Robert NJ, Muss HB, Piccart MJ, et al Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTGMA.17.J Natl Cancer Inst. 2005;97(17):1262-71. 158 Eiermann W, Paepke S, Appfelstaedt), Llombart-Cussac A, Eremin J, Vinholes j, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol. 2001;12(11):1527-32. 159 Recht A, Come SE, Henderson 1C, Gelman RS. Silver B, Hayes DF, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl j Med. 1996;334(21):1356^1. 160 Colleoni M, Bonetti M, Coafes AS, Castiglione-Gertsch M, Gelber RD, Price K, et al. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol. 2000; 18(31:584-90. 161 Shannon C, Ashley S, Smith IE. Does timing of adjuvant chemotherapy for early breast cancer influence survival? J Clin Oncol. 2003:21 (20):3792- 162 Bertelli G, Venturini M, Del Mastro L, Bergaglio M, Sismondi P, Biglia N, etal. Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol 2002; 13(6): 883-8. 163 Col NF, Hirota UCOrrRK. Hormonereplacementtherapyafterbreastcancer: 3 systemic review and quantative assessment of risk. J Clin Oncol 2001; 19:2357-63. 164 Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9382):419-27. 165 Pritehard, K. I., Khan, H., Levins, M. Steering Committee on Clinical Practice Guidelines for the care and treatment of breast cancer. Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer. CMAJ 2002. 16; 166(8): 1017-22. 166 Ambler N, Rumsey N, Harcourt D, Khan F, Cawthom S, Barker J Specialist nurse counsellor interventions at the time of diagnosis of breast cancer: comparing 'advocacy' with a conventional approach. I Adv Nurs. 1999;29(2):445-53. 167 Liebert B, Parle M, Roberts C, Redman S, Carrick 5, Gallagher J, et al. An evidence-based specialist breast nurse role in practice: a multicentre implementation study. Eur J Cancer Care (Engt) 2003;120):91-7. 168 Royal College of Nursing. A framework tor adult cancer nursing. London;TheColIege:2003. [cited 12 July 2005] Available from URL:: http:// www.rcn.org. uk/mernbers/downloads/RCNCancerFrameworkAug2QQ3. pdf 169 Maguire GP, Lee EC, Bevington D), Kuchemann CS, Crabtree RJ, Cornel! CE. Psychiatric problems in the first year after mastectomy. BMJ 1978;1.963-5. 170 Irvine RN, Brown 8, Crooks D, Roberts J, Browne C. Psychosocial adjustment in women with breast cancer. Cancer 1991 ;67:1097-117. 171 Kissane DW, Clarke DM. Ikm J, Bloch S, Smith GC. Vitetta L, et al. Psychological morbidity and quality of life in Australian women with early-stage breast cancer: a cross-sectional survey. Med J Aust 1998;169(4):192-6. 172 National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Guidelines for Supportive Care. Distress Management. [cited 28 September 2005]. Available from uri: http://www-nccn.org/ professionals/physician^gls/PDF/distress.pdf 173 Australia. National Breast Cancer Centre and National Cancer Control Initiative. Clinical practice guidelines for the psychosocial care of adults with cancer. Camperdown;National Breast Cancer Centre:2D03. 174 Morasso G, Costantini M, Viterbori P, Bonci F, Del Mastro L, Musso M, et al. Predicting mciod disorders in breast cancer patientS-Eur) Cane 2001:37: 216-23. 175 McLachlan SA, Devins GM, Goodwin PJ.Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) as a measure of psychosocial function in Breast cancer patients. EurJCancer 1998;34(4):510-7 176 Gilbody SM, House AO, Sheldon TA. Routinely administered questionnaires for depression and anxiety: systematic review. BMJ 2001;322(72B3):406-9. 177 Love AW, Kissane DW, Blcch S, Clarke D. Diagnostic efficiency of the Hospital Anxiety and Depression Scale in Women with early stage breast cancer Aust N Z J Psychiatry 2Q02;36:246-50. 178 Classen C, Butler LD, Koopman C, Miller E, DiMiceli S, Giese-Davis J, etal. Supportive-expressive group therapy and distress in patients with metastatic breast cancer: A randomized clinical intervention trial. Arch Gen Psychiatry 2001;58(5):494-501. 179 Goodwin P), Leszcz M, Ennis M, Koopmans J, Vincent L, Guther H, et al The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med 2001;345(24):1719-26. 180 Edmonds CV, Lockwood GA, Cunningham Al. Psychological response to long-term group therapy: a randomized trial with metastatic breast cancer patients. Psychoocology. 1999;8(1):74-91. 181 Simpson )S, Carlson LE. Trew ME Effect of group therapy for breast cancer on healthcare utilization. Cancer Pract. 20Q1;9fl):19-26. 182 Edelman S, Bell DR, Kidman AD. GroupCBT versus supportive therapy with patients who have primary breast cancer.j Cognitive Psychother 1999;13(3):189-202. 183 Edelman S, Bell DR, Kidman AD. A group Cognitive Behaviour Therapy programme with metastatic breast cancer patients.Psychooncology 1999:8(41:295-305 184 Kissane DW, Bloch S, Smith GC, Miach P, Clarke DM, Ikin). Cognitive-Existential Group Psychotherapy for women with primary breast cancer: a randomised controlled trial Psychooncology, 20Q3;12(6):532-46 185 Rustoen T, Wiklund I, Hanestad 8R, Mourn T. Nursing intervention to increase hope and quality of life in newly diagnosed cancer patients. Cancer Nurs. 1998;21(4):235-45. 186 Meyer T), Mark, MM. Effects of psychosocial interventions with adult cancer patients: a meta-analysis of randomized controlled experiments. Health Psychol. 1995:14:101-8. 187 Greer S, Moorey 5, Baruch |D, Watson M, Robertson BM, Mason A, et al. Adjuvant psychological therapy for patients with cancer: a prospective randomized trial. 1992;BM), 304: 675-80. 188 Devi ne EC, Westlake SK. The effects of psychoeducationa I interventions provided to adults with cancer: Meta analysis of 116 studies. Oncol Nurs Forum 1995;22(9):1369-81. 189 Nezu AM, Nezu CM, Felgoise SH, McClure KS, Houts PS. Project Genesis: assessing the efficacy of problem-solving therapy for distressed adult cancer patients. J Consult Clin Psychol 2003;71:1036-48. 190 Morrow GR, Dobkm PL. Anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment: prevalence, etiology and behavioural interventions. Clin Psychol Rev 1988;8:517-56. 191 Burish, TG, Smyder, SL, Jenkins RA. Preparing patients for cancer chemotherapy: effect of coping preparation and rebxation interventions. Jf Consult Clin Psychol 1991 ;59.518-25. 192 Allen SM, Shah AC, Nezu AM, Nezu CM, Ciambrone D, Hogan J. el al. A problem-solving approach to stress reduction among younger women with breast carcinoma: randomized controlled trial. Cancer 2002;94(12): 3089-100 193 Gustafson DH, Hawkins R, Pingree S, McTavish f, Arora NK, Mendenhalt J, et al. Effect of computer support on younger women with breast cancer. J Gen Intern Med»2001;16f7):435-45. 194 Rawl SM, Given BA, Given CW, Champion VL, Kozachik SL, Kozachik SL, et al. Intervention to improve psychological functioning for newly diagnosed patients with cancer. Oncol Nurs Forum. 2Q02,29(6):967-75. 195 Sandgren AK. McCaul KD, King 8, O'Donnell S, Foreman G. Telephone therapy for patients with breast cancer. Oncol Nurs Forum. 2QQO;27(4):683-8. 196 Newell SA, Sanson-Fisher RW, Savolainen Nj. Systematic review of psychological therapies for cancer patients: overview and recommendations for future research.) Natl Cancer Inst. 2002;94{S):S58-84. 197 McPherson CJ, Higgmson I), Hearn ). Effective methods of giving information in cancer" a systematic literature review of randomized controlled trials. J Public Health Med. 2001;23(3):227-34. 198 Deadman JM, Leinster SJ, Owens RG, Dewey ME, Slade PD. Taking responsibility for cancer treatment. Soc Sci Med. 2001;53(5):669-77. 199 Kissane DW. Burke 5. Psychosocial support for breast cancer patients provided by members of the treatment team: a summary of the literature 1976-1996. King's Cross(NSW);NHMRC National Breast Cancer Centre: 1996 [cited 12 July 2005] Available from URL: http://www. nbcc.org.au/bestpractice/resou rces/MTT_psychosocialsupport. pdf 200 Faftawfield Lf. Hall A. Maguire P. Baum M. A'Hern RP. A question of choice: results of a prospective 3 year follow up study of women with breast cancer. Breast 1994;3(4):202-8. 201 Sepucha KR. Belkora !K, Mutchnick S, Esserman LJ. Consultation planning to help breast cancer patients prepare for medical consultations: effect on communication and satisfaction for patients and physicians.) Clin Oncol. 2002;20(11):2695-7QQ. 202 Bruera E, Sweeney C, Wrlfey J, Palmer JL, Tolley S, Rosales M, et al. Breast cancer patient perception of the helpfulness of a prompt sheet versus a general information sheet during outpatient consultation: A randomized, controlled trial j Pain Symptom Manage. 20Q3;25(5):412-9. 203 Whelan T, Sawka C, Levine M, Gafni A, Reyno L, Willan A, et al. Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer.[comment]. J Natl Cancer Inst. 2003;16;95(8):581-7. 204 Fellowes D, Wilkinson S, Moore P. Communication skills training for health care professionals working with cancer patients, their families and/or carers (Ccchrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford;Update Software 205 Rojas MP, Telaro E, Russo A, Moschetti I. Coe L, Fossati R, et at. Follow-up strategies for women treated for early breast cancer (Cochrane Review). In: The Cochrane Library, Issue 4, 2004. Oxford, Update Software. 206 Grunfeid E, Mant D, Yudkin P, Adewuyi-Dalton R, Cole D, Stewart |, Fitzpatrick R, Vessey M. Routine follow up of breast cancer in primary care: randomised trial. British Medical Journal 1996;313(7058):665-9. 207 Gulliford T, Opomo M, Wilson E, Hanham I, Epstein R. Popularity of less frequent follow-up for breast cancer in randomised study: initial findings from the hotline study. British Medical Journal 1997;314:171-7. 208 Brown L, Payne S, Royle G. Patient initiated follow up of breast cancer. Psychooncology 2002:11:346-55. 209 Grunfeid E, Noorani H, McGahan L, Paszat L, Coyle D, van Walraven C, et al. Surveillance mammography after treatment of primary breast cancer: a systematic review. Breast 2002;! 1 (3):228-35. 210 Flobbe K, van der Linden ES, Kessels AC, van Engelshoven JM. Diagnostic value of radiological breast imaging in a non-screening population. IntJCancer. 2001;92(4):6l6-8. 211 Clinical Standards Board for Scotland. Clinical Standards: Specialist Palliative Care. Rev ed. Edinburgh;Clinica! Standards Board for Scotland:2002. [cited 12 July 2005] Available from URL: httpV/www. nh5healthquality.org/nhsqi5/filesfiPC.pdf 212 Scottish Intercollegiate Guidelines Network (SIGN) Control of pain in patients with cancer. Edinburgh:SIGN; 2000. (SIGN guideline no.44). [cited 12 July 2QD5] Available from URL: http://www.sign.ac.uk/pdf/ sign44.pdf 213 HeamJ.HigginsonlJ. DospecialistpalliativecaretEamsimproveoutcomes for cancer patients? A systematic literature review. PalliatMed. 1998,12(5): 317-32. 214 Homsi J, Walsh D, Nelson KA, LeGrand SB, Davis M, Khawarn E, et al. The impact of a palliative medicine consultation service in medical oncology. Support Care Cancer. 2Q02;1Q(4):337-42. 215 F. Cardoso, E. Senkus-Konefka, L. Fallowfield, A. Costa & M. Castiglione. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Annals of Oncology 21 (Supplement 5): v9–v14, 2010 doi:10.1093/annonc/mdq159 http://www.esmo.org/education/practice-tools.html 216 S. Aebi1, T. Davidson, G. Gruber & M. Castiglione Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Annals of Oncology 21 (Supplement 5): v9–v14, 2010 http://www.esmo.org/education/practice-tools.html 217 J. Balmana, O. Diez, I. Rubio & M. Castiglione BRCA in breast cancer: ESMO Clinical Practice Guidelines Annals of Oncology 21 (Supplement 5): v20–v22, 2010 http://www.esmo.org/education/practice-tools.html 218 Advanced breast cancer. Diagnosis and treatment. National Collaborating Centre for Cancer. NGC:007179 AHRQ (US) - Agency for Healthcare Research and Quality Feb 01, 2009. 219 Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care (partial update of CG14) (CG41) NICE (GB) - National Institute for Health and Clinical Excellence Oct 01, 2006 220 Early and locally advanced breast cancer. Diagnosis and treatment. National Collaborating Centre for Cancer. NGC:007180 AHRQ (US) - Agency for Healthcare Research and Quality Feb 01, 2009. 221 Management of Early Breast Cancer NZGG (NZ) - New Zealand Guidelines Group Aug 01, 2009. СПИСОК ЛіТЕРАТУРи, використанИЙ В ПРОЦЕСІ АДАПТАЦІЇ клінічної настанови
жүктеу/скачать 1.3 Mb. Достарыңызбен бөлісу:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||